Current Knowledge About Aprocitentan in Hypertension

Hypertension (HT) is the leading contributor to the global burden of disease and overall mortality and is expected to increase due to such factors as increased life expectancy and rising obesity rates. Although HT significantly contributes to cardiovascular disease, it is also considered one of the most modifiable risk factors. Aprocitentan (ACT) is a newly developed orally administered dual endothelin receptor antagonist. This review aims to give an overview of the current knowledge regarding ACT in HT, focusing on its pharmacological mechanisms and therapeutic potential. We conducted a search in the PubMed and Clinicaltrials.gov databases using the search terms "hypertension", "aprocitentan", high blood pressure" and "cardiovascular disease", as well as all their permutations. Both human and animal studies have demonstrated significant blood pressure reductions within 14 days of administration, with 25 mg identified as the most effective dose and no severe adverse effects. Moreover, ACT was compatible with other antihypertensive agents, demonstrating synergistic or additive effects in some cases. Since HT is frequently associated with comorbidities and ACT targets a different pathway than the existing antihypertensive drugs, ACT may play a pivotal role in the management of resistant hypertension.